{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    15,
    17,
    18,
    19,
    20,
    23,
    24,
    25,
    26,
    27,
    30,
    31
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "PD-L1 Population Definition",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.5.1",
        "sectionTitle": "Archived Tumor Biospecimens and De Novo Tumor Biopsies",
        "description": "Reference for the prospectively defined PD-L1 positive patient population"
      },
      {
        "id": "ref_2",
        "name": "Treatment Continuation Details",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.4.4",
        "sectionTitle": "Treatment After Initial Evidence of Radiologic Disease Progression in Both Arms",
        "description": "Details on treatment continuation after initial evidence of disease progression"
      },
      {
        "id": "ref_3",
        "name": "Withdrawal Criteria",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.5",
        "sectionTitle": "Patient Withdrawal",
        "description": "Reference to study withdrawal criteria and procedures"
      },
      {
        "id": "ref_4",
        "name": "Dose Modifications",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.4.6",
        "sectionTitle": "Recommended Dose Modifications",
        "description": "Reference for axitinib and avelumab treatment adjustments for toxicities"
      },
      {
        "id": "ref_5",
        "name": "Testing Strategy Figure",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.1",
        "sectionTitle": "Sample Size Determination",
        "description": "Reference to Figure 2 for the gatekeeping procedure and testing strategy"
      },
      {
        "id": "ref_6",
        "name": "Statistical Significance Levels",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.6",
        "sectionTitle": "Interim Analysis",
        "description": "Reference for group sequential design significance levels"
      },
      {
        "id": "ref_7",
        "name": "Contraception Methods",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.3.1",
        "sectionTitle": "Contraception",
        "description": "Reference to allowed methods of contraception"
      },
      {
        "id": "ref_8",
        "name": "Laboratory Test Requirements",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 7",
        "sectionTitle": "Required Laboratory Tests",
        "description": "Reference for required hematology and chemistry tests"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Weight will be collected before each avelumab infusion.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 24
      },
      {
        "id": "annot_2",
        "text": "Patients will monitor their blood pressure at least once daily... and blood pressure should be recorded in a patient diary.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 25
      },
      {
        "id": "annot_3",
        "text": "irRECIST-defined antitumor activity will no longer be collected as per PACL dated 02 September 2019.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 26
      },
      {
        "id": "annot_4",
        "text": "Arm A: troponin test results must be reviewed by the treating physician before each avelumab administration.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 28
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "8",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-01-03",
        "description": "Final Protocol Amendment 8",
        "amendmentNumber": "Amendment 8"
      }
    ],
    "summary": {
      "referenceCount": 8,
      "annotationCount": 4,
      "versionCount": 1
    }
  }
}